Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
China · Delayed Price · Currency is CNY 25.02
-0.94 (-3.62%)
May 12, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,694 | 1,635 | 1,139 | 966.95 | 934.11 | 964.74 |
Other Revenue | 46.34 | 46.34 | 61.09 | 52.81 | 88.79 | 31.48 |
| 1,740 | 1,681 | 1,200 | 1,020 | 1,023 | 996.22 | |
Revenue Growth (YoY) | 24.98% | 40.07% | 17.71% | -0.31% | 2.68% | 28.14% |
Cost of Revenue | 1,157 | 1,162 | 1,006 | 809.11 | 800.16 | 727.71 |
Gross Profit | 583.8 | 518.76 | 194.72 | 210.65 | 222.75 | 268.51 |
Selling, General & Admin | 158.75 | 150.39 | 118.74 | 131.31 | 101.98 | 88.49 |
Research & Development | 89.84 | 79.82 | 55.8 | 44.6 | 40.14 | 46.89 |
Other Operating Expenses | 7.46 | 4.14 | 3.52 | 3.23 | 8.84 | 4.92 |
Operating Expenses | 260.99 | 239.28 | 176.37 | 204.08 | 161.73 | 133.23 |
Operating Income | 322.8 | 279.47 | 18.35 | 6.57 | 61.01 | 135.28 |
Interest Expense | -13.62 | -13.62 | -42.66 | -28.22 | -18.38 | -2.87 |
Interest & Investment Income | 11.55 | 10.92 | 10.03 | 17.47 | 10.31 | 10.54 |
Currency Exchange Gain (Loss) | -0.83 | -0.83 | 0.69 | -0.16 | -0.03 | -0.03 |
Other Non Operating Income (Expenses) | 8.72 | -2.29 | -1.35 | -0.62 | -0.67 | -0.47 |
EBT Excluding Unusual Items | 328.63 | 273.66 | -14.96 | -4.95 | 52.24 | 142.45 |
Gain (Loss) on Sale of Investments | -16.26 | 1.2 | -23.64 | 12.25 | 1.46 | 1.55 |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.01 | -0.06 |
Asset Writedown | -1.46 | -0.61 | -0.21 | - | - | - |
Other Unusual Items | 14.4 | 14.4 | 9.83 | 5.14 | 3 | 6.89 |
Pretax Income | 325.31 | 288.65 | -28.97 | 12.44 | 56.71 | 150.83 |
Income Tax Expense | 38.36 | 35.17 | -9.2 | -4.34 | 4 | 17.97 |
Earnings From Continuing Operations | 286.96 | 253.49 | -19.77 | 16.78 | 52.71 | 132.87 |
Minority Interest in Earnings | -0.62 | -0.33 | -0.38 | - | - | - |
Net Income | 286.33 | 253.16 | -20.16 | 16.78 | 52.71 | 132.87 |
Net Income to Common | 286.33 | 253.16 | -20.16 | 16.78 | 52.71 | 132.87 |
Net Income Growth | 602.71% | - | - | -68.16% | -60.33% | -11.52% |
Shares Outstanding (Basic) | 199 | 190 | 166 | 166 | 165 | 166 |
Shares Outstanding (Diluted) | 202 | 196 | 166 | 166 | 165 | 166 |
Shares Change (YoY) | 19.57% | 18.13% | -0.06% | 0.33% | -0.19% | 12.59% |
EPS (Basic) | 1.44 | 1.33 | -0.12 | 0.10 | 0.32 | 0.80 |
EPS (Diluted) | 1.42 | 1.29 | -0.12 | 0.10 | 0.32 | 0.80 |
EPS Growth | 487.72% | - | - | -68.27% | -60.25% | -21.41% |
Free Cash Flow | 103.52 | 141.53 | -150.89 | -91.39 | -332.18 | -444.4 |
Free Cash Flow Per Share | 0.51 | 0.72 | -0.91 | -0.55 | -2.01 | -2.68 |
Dividend Per Share | 0.300 | 0.300 | 0.106 | 0.270 | 0.300 | 0.331 |
Dividend Growth | 181.91% | 181.91% | -60.59% | -10.00% | -9.37% | 21.11% |
Gross Margin | 33.54% | 30.86% | 16.22% | 20.66% | 21.78% | 26.95% |
Operating Margin | 18.55% | 16.62% | 1.53% | 0.64% | 5.96% | 13.58% |
Profit Margin | 16.45% | 15.06% | -1.68% | 1.65% | 5.15% | 13.34% |
Free Cash Flow Margin | 5.95% | 8.42% | -12.57% | -8.96% | -32.48% | -44.61% |
EBITDA | 444.86 | 399.78 | 131.63 | 126.96 | 123.58 | 163.82 |
EBITDA Margin | 25.56% | 23.78% | 10.97% | 12.45% | 12.08% | 16.44% |
D&A For EBITDA | 122.06 | 120.3 | 113.29 | 120.39 | 62.57 | 28.54 |
EBIT | 322.8 | 279.47 | 18.35 | 6.57 | 61.01 | 135.28 |
EBIT Margin | 18.55% | 16.62% | 1.53% | 0.64% | 5.96% | 13.58% |
Effective Tax Rate | 11.79% | 12.18% | - | - | 7.06% | 11.91% |
Revenue as Reported | 1,681 | 1,681 | 1,200 | 1,020 | 2,046 | 996.22 |
Advertising Expenses | - | 16.28 | 6.83 | 6.78 | 3.2 | 1.71 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.